JAZZ — Jazz Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $13.92bn
- $16.07bn
- $4.27bn
Amneal Pharma up after US FDA approves sodium oxybate solution
Brief: Modeyso™ (dordaviprone) Added to NCCN Guidelines for H3 K27M-Mutant Diffuse Glioma
U.S. RESEARCH ROUNDUP-Agilent Technologies, Nvidia, Snowflake
US FDA approves Jazz Pharma's drug for rare brain tumor (updated)
US FDA approves Jazz Pharma's drug for rare brain tumor
Jazz Pharmaceuticals PLC reports results for the quarter ended June 30 - Earnings Summary
Brief: Jazz Pharmaceuticals Renee Gala Named As President And CEO Effective August 11 - SEC Filing
Brief: Jazz Pharmaceuticals Q2 Adjusted EPS USD -8.25 Vs. IBES Estimate USD -7.61
Brief: Jazz Pharmaceuticals Names Renee Gala As President And CEO
ASL pushes for board shakeup at Avadel over handling of sleep drug rollout
EU reviews risk of abuse in some treatments for alcohol dependency (updated)
Brief: US FDA Grants Priority Review to Zepzelca + Tecentriq for 1st-Line ES-SCLC Maintenance Therapy
Brief: Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (Calcium, Magnesium, Potassium, And Sodium Oxybates) Oral Solution Treatment Outcomes In Narcolepsy At Sleep 2025
Brief: Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination
Prices for new US drugs doubled in 4 years as focus on rare disease grows
Hikma Pharma to pay $50 million to settle narcolepsy drug antitrust case
Jazz Pharmaceuticals PLC reports results for the quarter ended March 31 - Earnings Summary
Brief: Jazz Pharmaceuticals Q1 Adjusted EPS USD 1.68 Vs. IBES Estimate USD 4.66
RCS - Redx Pharma Limited - Redx presents Ph1 data supporting RXC008 at DDW